Ad-IL-17AR:Fc administration reduces IL-17A production in the blood and the heart.

<p>(<i>A</i>) Serum IL-6 concentrations at post-infection 7 days, 2mons and 3mons in PBS-, Ad-IL-17AR:Fc- and Ad:null-treated mice (n = 5) were measured using ELISA, and the data were analyzed by a 2-factor ANOVA. <sup>##</sup><i>p</i><0.01, <sup>#</sup><i>p</i><0.05 vs 7 Days group, **<i>p</i><0.01, *<i>p</i><0.05 vs control group, (<i>B</i>) Serum TNF-α concentrations at post-infection 7 days, 2mons and 3mons in PBS-, AdIL-17R:Fc- and Ad:null-treated mice (n = 5) were measured using ELISA, and the data were analyzed by a 2-factor ANOVA. <sup>#</sup><i>p</i><0.05 vs 7 Days group, *<i>p</i><0.05 vs control group. The data represent the mean ± SEM for 6 mice per group. (<i>C</i>)The IL-17A protein extracted from the left ventricle of the mice in the three groups at post-infection day 90, was subjected to western blotting and was probed with the indicated antibodies (n = 3). (D)The IL-17A protein level is expressed as a ratio of the GAPDH level in the same sample; the data are expressed as the mean± SEM. *<i>P</i><0.05 vs the control group. (<i>E</i>) The IL-17RA protein extracted from the left ventricle of the mice in the three groups at post-infection day 90, was subjected to western blotting and was probed with the indicated antibodies (n = 3). (<i>F</i>) The IL-17RA protein level is expressed as a ratio of the GAPDH level in the same sample; the data are expressed as the mean± SEM.</p>